Shanghai-based JS InnoPharm Ltd has announced an agreement with US firm Strategia Holdings LLC to establish JSI Ventures Inc. (JSV) in Boston, Massachusetts. The new venture aims to comprehensively integrate management teams and new drug research and development (R&D) projects from both companies. Dr. Keizo Koya, founder of Strategia, will serve as the general manager of JSI Ventures and will join JS InnoPharm’s board of directors.
Partnership Background
Founded in 2012, Strategia has launched 17 new drugs in the US. The partnership with JS InnoPharm began in 2018 with the joint development of E6201, a MEK kinase inhibitor with high blood-brain penetrability. In 2019, JS InnoPharm entrusted Strategia to conduct clinical studies for its ERK kinase inhibitor JSI-1187 in the US. The collaboration further expanded in 2020 with the establishment of Vitrac Therapeutics LLC, a joint venture focused on developing the Aurora A kinase inhibitor VIC-1911.
Future Implications
The formation of JSI Ventures represents a significant expansion of JS InnoPharm’s presence in the US market. By integrating resources and expertise, the new venture aims to accelerate the development and commercialization of innovative drugs, leveraging the strengths of both JS InnoPharm and Strategia Holdings.-Fineline Info & Tech
